Prescription medication · Soluble Guanylate Cyclase Stimulator
vericiguat
Also sold as Verquvo. Verquvo helps to reduce the risk of dying from heart problems.
Data updated 2026-05-15
- 905
- FDA reportsRarely reported
- $21.57
- Brand price (NADAC)
vericiguat (Verquvo) is a prescription Soluble Guanylate Cyclase Stimulator. Verquvo helps to reduce the risk of dying from heart problems.
Verquvo is a medicine that helps lower the risk of death and hospitalization from heart failure. It is for adults with long-term heart failure and a weak heart pump (ejection fraction less than 45%).
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$21.57/unit
Generic Available
No
MSD
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Verquvo helps to reduce the risk of dying from heart problems.
Common side effects
Low blood pressure, Anemia (low red blood cell count)
Key warnings
Verquvo can harm an unborn baby.
The sections below are summarized in plain English from vericiguat's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Verquvo is a soluble guanylate cyclase (sGC) stimulator. It works by helping blood vessels relax and widen. This makes it easier for your heart to pump blood.
Side Effects (from patient reports)
Based on 905 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for vericiguat, by number of reports
- Hypotension
Hypotension
106 reports
- Death
Death
90 reports
- Dizziness
Dizziness
65 reports
- Cardiac Failure
Cardiac Failure
60 reports
- Anaemia 35
Anaemia
35 reports
- Fatigue 35
Fatigue
35 reports
- Blood Pressure Decreased 34
Blood Pressure Decreased
34 reports
- Malaise 34
Malaise
34 reports
- Dyspnoea 32
Dyspnoea
32 reports
- Nausea 29
Nausea
29 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for vericiguat each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where vericiguat sits
vericiguat has more FDA adverse-event reports than 6% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is vericiguat; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 905 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2017–2025.
Total Reports
905
Reports Mentioning Death
135
14.9% of reports — not proof of cause
Hospitalization Reports
215
Top Indication
Cardiac Failure
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | HYPOTENSION | 106 |
| 2 | DEATH | 90 |
| 3 | DIZZINESS | 65 |
| 4 | CARDIAC FAILURE | 60 |
| 7 | ANAEMIA | 35 |
| 8 | FATIGUE | 35 |
| 9 | BLOOD PRESSURE DECREASED | 34 |
| 10 | MALAISE | 34 |
| 11 | DYSPNOEA | 32 |
| 12 | NAUSEA | 29 |
| 13 | ASTHENIA | 27 |
| 14 | DIARRHOEA | 27 |
| 17 | RASH | 21 |
| 18 | HEADACHE | 20 |
| 19 | HOSPITALISATION | 19 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Verquvo can harm an unborn baby. If you are a woman who can get pregnant, you must have a pregnancy test before starting Verquvo. You must use effective birth control while taking Verquvo and for 1 month after your last dose.
Common Questions
What should I do if I feel dizzy after taking Verquvo?
Can I take Verquvo with my other heart medications?
How long will I need to take Verquvo?
Can I drink alcohol while taking Verquvo?
What should I do if I have side effects?
Is it okay to stop taking Verquvo if I feel better?
Will Verquvo cure my heart failure?
How often will I need to see my doctor while taking Verquvo?
Can I drive while taking Verquvo?
What if I have trouble paying for my Verquvo prescription?
What are the common side effects of vericiguat?
What drug class is vericiguat?
What pregnancy or breastfeeding source fields are listed for vericiguat?
Related Medications in Soluble Guanylate Cyclase Stimulator
Other drugs grouped near vericiguat - same-class peers and common alternatives.
adenosine
Adenocard
Adenosine (Adenocard) is a medicine used to treat certain types of irregular heartbeats.
Compare with vericiguat →
amiodarone
Cordarone, Pacerone
Amiodarone (Pacerone) is a medicine used to treat life-threatening, irregular heartbeats.
Compare with vericiguat →
atropine
AtroPen
Atropine is a medicine that can temporarily block severe effects on your body.
Compare with vericiguat →
bumetanide
Bumex
Bumetanide is a water pill (diuretic).
Compare with vericiguat →
carvedilol
Coreg
Carvedilol is a medicine that lowers blood pressure and helps your heart work better.
Compare with vericiguat →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for vericiguat: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 905.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 14.92%.
- memantine Δ 0.18 pts · 12,807 reports · NMDA Receptor Antagonist 15.10%death share
- oseltamivir Δ 0.25 pts · 7,575 reports · Neuraminidase Inhibitor (Antiviral) 15.17%death share
- sildenafil Δ 0.25 pts · 55,325 reports · PDE5 Inhibitor 15.17%death share
- diltiazem Δ 0.29 pts · 33,620 reports · Calcium Channel Blocker 14.63%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on vericiguat
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for vericiguat
The FDA label for vericiguat (sold under brand names such as Verquvo) classifies it as a prescription-only medication in the Soluble Guanylate Cyclase Stimulator class. Verquvo helps to reduce the risk of dying from heart problems. Official labeling lists 2 commonly reported side effects, including Low blood pressure, Anemia (low red blood cell count).
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 905 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: January 21, 2026
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages